COVID-19 may become nanomedicine's finest hour yet.

Friedrichs, Steffi; Bowman, Diana M

Friedrichs, Steffi; Bowman, Diana M.

Friedrichs S; AcumenIST, Brussels, Belgium. steffi@acumenist.com.
Bowman DM; Sandra Day O'Connor College of Law, Arizona State University, Phoenix, AZ, USA.

Nat Nanotechnol ; 16(4): 362-364, 2021 04.

Article in English | MEDLINE | ID: covidwho-1182835

Subject(s)

COVID-19 Vaccines/pharmacology; COVID-19/prevention & control; Nanomedicine/methods; Pandemics; SARS-CoV-2; 2019-nCoV Vaccine mRNA-1273; BNT162 Vaccine; COVID-19/epidemiology; COVID-19/immunology; Drug Approval; Drug Delivery Systems/methods; Drug Development/methods; Drug Development/trends; Global Health; Humans; Nanomedicine/trends; Nanotechnology/methods; Nanotechnology/trends; Pandemics/prevention & control; RNA, Messenger/genetics; SARS-CoV-2/genetics; SARS-CoV-2/immunology; Time Factors; Vaccines, Synthetic/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanomedicine / Pandemics / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Nanotechnol Year: 2021 Document Type: Article Affiliation country: S41565-021-00901-8

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google